BeyondSpring, Inc.

NASDAQ:

BYSI

BeyondSpring, Inc. develops innovative immuno-oncology cancer therapies with a robust pipeline from internal development and collaboration with the University of Washington in de novo drug discovery using an ubiquitination platform. BeyondSpring's lead asset, plinabulin, is in two phase 3 global clinical trials as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and the prevention of chemotherapy-induced neutropenia (CIN).

Key Facts

Auditor

Public Listing

Domicile

HQ/Management

Location of Key Operations

IR Contact

Ernst & Young Hua Ming LLP

IPO (March 9, 2017)

Delaware

New York, New York, USA

Ashley R. Robinson, Internal

617-430-7577

Analyst Coverage

Latest News